US FDA advisory committee votes in favour of approving terlipressin for Hepatorenal Syndrome Type 1 (HRS-1)

Terlipressin, a vasopressin analogue has been shown in trials, to be effective at reversal of this acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis, resulting in renal function improvement, avoidance of dialysis and short-term survival.